Association of Diaphragm Involvement Assessed by Ultrasound With Disease Severity in Facioscapulohumeral Muscular Dystrophy

Xiang Xu, Fuze Zheng, Xin Lin, Liangliang Qiu, Long Chen, Jing Xu, Kang Li, Jie Chen, Liulei Wu, Ying Zheng, Minghui Zeng, Xiaodan Lin, Qifang He, Li Chen, Lin Feng, Ning Wang, Min‐Ting Lin, Guorong Lyu, Zhiqiang WangJournal of Cachexia Sarcopenia and Muscle 2025 · DOI

TL;DR

This study demonstrates that ultrasound measurements of diaphragm function (specifically excursion velocity and relaxation rate) can effectively identify respiratory involvement and predict disease severity in patients with Facioscapulohumeral Muscular Dystrophy (FSHD1). These non-invasive ultrasound parameters show promise as valuable biomarkers for clinical assessment and future trials.

What Problem Does This Paper Address?

Facioscapulohumeral Muscular Dystrophy (FSHD1) is a progressive neuromuscular disorder that can lead to significant respiratory complications, including restrictive ventilatory defects (RVD). However, standard pulmonary function tests (PFTs) used to assess respiratory health can be unreliable in FSHD1 patients due to facial muscle weakness, which impairs their ability to properly seal their mouths around spirometry equipment. This makes it challenging to accurately gauge the extent of respiratory involvement and its impact on disease severity. The paper aims to address this by investigating the utility of diaphragm ultrasound as a more reliable and accessible method for assessing diaphragm function and its association with respiratory issues and overall disease progression in FSHD1.

Methods

The researchers conducted a prospective, observational case-control study. They enrolled genetically confirmed FSHD1 patients and matched control participants. The core of their methodology involved:

  • Diaphragm Ultrasound: This was the primary assessment tool. They used both M-mode and B-mode ultrasound to measure several parameters of the diaphragm's function, including:
  • Diaphragm excursion velocity (V<sub>VS</sub>): The speed at which the diaphragm moves during a maximal sniff.
  • Maximal relaxation rate of the diaphragm (ECHO-MRR): The rate at which the diaphragm relaxes after a sniff.
  • Diaphragm excursion at total lung capacity (ETLC): The total distance the diaphragm moves from its resting to its fully contracted position.
  • Diaphragm thickness at functional residual capacity (ThFRC) and total lung capacity (ThTLC): Measurements of diaphragm thickness at different lung volumes.
  • Diaphragm thickening ratio (DTR): A ratio of thickness at TLC to FRC, indicating the degree of thickening during contraction.
  • Pulmonary Function Tests (PFTs): Standard PFTs (FVC and FEV1) were performed to assess respiratory function and identify RVD. Special measures, like manual mouth support, were used to mitigate the impact of facial weakness.
  • Clinical Assessments: This included collecting data on the number of contracted D4Z4 repeat units (a genetic marker for FSHD1), muscle strength (using the MRC scale), and disease severity using established clinical scores (FSHD clinical score, CSS, and age-corrected CSS).
  • Statistical Analysis: Various statistical methods were employed, including Mann-Whitney U tests, Kruskal-Wallis H tests, chi-squared tests, Spearman correlation coefficients, and multivariate linear regression models. Receiver operating characteristic (ROC) curve analysis was used to determine the predictive ability of ultrasound parameters for RVD. Kaplan-Meier curves and Cox proportional hazards regression were used to assess the association with lower extremity involvement.

Datasets

The study utilized data from two cohorts:

  • Exploration Cohort: 81 FSHD1 patients and 162 matched control participants.
  • Validation Cohort: An additional 28 FSHD1 patients were used to validate the findings related to predicting RVD.

The study did not introduce a new benchmark dataset but rather collected data on existing FSHD1 patients and controls.

Key Insights and Ideas

  • Ultrasound as a Reliable Indicator: The study strongly suggests that diaphragm ultrasound parameters, particularly V<sub>VS</sub> and ECHO-MRR, are not only measurable but also highly informative for assessing diaphragm function in FSHD1 patients, even when PFTs are compromised.
  • Diaphragm Weakness is Pervasive: All measured diaphragm ultrasound parameters were significantly lower in FSHD1 patients compared to controls, confirming widespread diaphragm involvement in the disease.
  • Predicting Respiratory Issues: The V<sub>VS</sub> and ECHO-MRR parameters, especially from the right hemidiaphragm, showed significant predictive power for identifying RVD in FSHD1 patients, with a multivariate model achieving a high AUC of 0.943. This is a crucial finding given the limitations of PFTs.
  • Biomarkers for Disease Severity: Lower V<sub>VS</sub> and ECHO-MRR values were negatively correlated with age-corrected clinical severity scores (ACSS), indicating that poorer diaphragm function is associated with more severe disease.
  • Lower Extremity Involvement Link: Patients with lower V<sub>VS</sub> were found to have a significantly earlier onset of lower extremity involvement, suggesting that diaphragm health can be an early indicator of broader disease progression.
  • Early Onset FSHD1 is More Severe: Early-onset FSHD1 patients showed more pronounced diaphragm impairment and a higher frequency of RVD compared to typical onset patients, highlighting the importance of early assessment in this subgroup.

Key Results

  • Reduced Diaphragm Function: FSHD1 patients exhibited significantly lower V<sub>VS</sub>, ECHO-MRR, ETLC, ThFRC, and ThTLC compared to controls (all p<0.0001).
  • RVD Prediction: The V<sub>VS</sub> parameter achieved an AUC of 0.900 for predicting RVD, and a multivariate model (V<sub>VS</sub>, ECHO-MRR, age, sex, D4Z4 RUs) achieved an AUC of 0.943. The validation cohort showed high true positive rates (80.0%) for V<sub>VS</sub> and ECHO-MRR in identifying RVD.
  • Disease Severity Correlation: Lower right hemidiaphragm V<sub>VS</sub> (β=-1.686) and ECHO-MRR (β=-1.761) were significantly associated with higher age-corrected CSS.
  • Lower Extremity Involvement: Patients in the low V<sub>VS</sub> subgroup had a significantly earlier onset of LE involvement (log-rank p=0.0007). Cox regression indicated that low V<sub>VS</sub> and ECHO-MRR subgroups had a significantly higher risk of developing LE involvement (aHRs of 2.353 and 2.039, respectively).
  • Early Onset Impact: Early-onset FSHD1 patients showed significantly reduced right hemidiaphragm parameters and a higher frequency of RVD compared to typical onset patients.

Limitations and Future Work

The authors acknowledge several limitations:

  • Prospective Design & Limited Follow-up: The study design and limited follow-up period prevented them from definitively determining if patients without RVD or with lower V<sub>VS</sub> would eventually develop more severe clinical outcomes like loss of ambulation.
  • Asymptomatic Carriers: The study did not investigate asymptomatic FSHD1 carriers, leaving open the question of whether diaphragm involvement precedes or follows limb muscle weakness.
  • PFT Position Sensitivity: While a small subset (n=7) showed no significant difference in PFTs between seated and supine positions, a larger-scale assessment is needed to confirm this, as supine PFTs are generally considered more sensitive for diaphragm involvement.
  • Severely Wheelchair-Dependent Patients: The study lacked severely wheelchair-dependent patients, limiting conclusions about diaphragm involvement in those with the most advanced symptoms.

Future work could explore these limitations by conducting longitudinal studies with longer follow-up periods, including asymptomatic carriers, and investigating a broader range of patient severity. The authors suggest that diaphragm ultrasound parameters could serve as valuable biomarkers for disease severity and prognosis in FSHD1, warranting further investigation for their role in clinical trials and patient management.

Summary updated

Abstract

Ultrasound parameters, including V<sub>VS</sub> and ECHO-MRR, are informative for assessing diaphragm involvement and respiratory involvement in FSHD1. This knowledge establishes diaphragm ultrasound parameters as potential biomarkers of FSHD1 disease severity in upcoming clinical trials.
BibTeX
@article{xu2025association,
  author = {Xiang Xu and Fuze Zheng and Xin Lin and Liangliang Qiu and Long Chen and Jing Xu and Kang Li and Jie Chen and Liulei Wu and Ying Zheng and Minghui Zeng and Xiaodan Lin and Qifang He and Li Chen and Lin Feng and Ning Wang and Min‐Ting Lin and Guorong Lyu and Zhiqiang Wang},
  title = {{Association of Diaphragm Involvement Assessed by Ultrasound With Disease Severity in Facioscapulohumeral Muscular Dystrophy}},
  journal = {Journal of Cachexia Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.70057},
}
Figure